HomeAI · summaries
Storia in 9 fonti
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
Novartis pays $1.1B upfront (up to $1.5B total) for Myricx Bio, gaining its NMT inhibitor ADC payload platform and two preclinical oncology assets.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis to acquire ADC developer in a deal worth up to $1.5B
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
- ·
morningstar.com
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
